Ion-682884
Web13 nov. 2024 · ION-682884-CS2 (EudraCT No: 2024-002835-27) is a Phase 3 global, double-blind, randomized, placebo-controlled study assessing the efficacy and safety of … Web10 apr. 2024 · Coelho T, Ando Y, Benson MD, et al. Design and rationale of the global phase 3 NEURO-TTRansform study of antisense oligonucleotide AKCEA-TTR-LRx (ION-682884-CS3) in hereditary transthyretin-mediated amyloid polyneuropathy. Neurol Ther. 2024;10(1):375–89. Article PubMed PubMed Central Google Scholar
Ion-682884
Did you know?
Web13 nov. 2024 · ION-682884-CS2 (EudraCT No: 2024-002835-27) is a Phase 3 global, double-blind, randomized, placebo-controlled study assessing the efficacy and safety of … Web27 mrt. 2024 · AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines in …
Web26 nov. 2024 · Akcea Therapeutics and Ionis Pharmaceuticals announced the launch of a Phase 3 clinical trial evaluating the safety and efficacy of AKCEA-TTR-L Rx (ION-682884) for the treatment of adults with familial amyloid polyneuropathy (FAP). The global, open-label, randomized NEURO-TTRansform trial ( NCT04136184) is expected to start in … Web23 nov. 2024 · These antisense therapies rely on modified nucleotides sequences (single-strand DNA or RNA, both belonging to the antisense oligonucleotides family, or double-strand interfering RNA) to act specifically on pathogenic target nucleic acids, thanks to complementary base pairing.
WebA Phase 3 Global, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ION-682884 in Patients With Transthyretin-Mediated Amyloid … WebA Study to Assess the Long-Term Safety and Efficacy of ION-682884 in Patients With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy This is a multicenter, open …
WebION-682884. Volwassenen met met familiale transthyretine-gemedieerde amyloïde polyneuropathie. NL74259.000.20. RO7248824. Gezonde volwassen mannen. NL75028.000.21. ION373. Kinderen van 2 jaar en ouder, adolescenten en volwassenen met de ziekte van Alexander. NL75086.000.20. AKCEA-APOCIII-LRX (ISIS678354), …
Web15 apr. 2024 · This study aims to determine whether subcutaneous injection of an antisense oligonucleotide drug, known as ION-682884, that has been specifically designed to … highdown inn iowWebTo evaluate the efficacy of ION-682884 after administration for 65 weeks, as compared to the historical control of the placebo cohort in the NEURO-TTR trial, based on the change … how fast do owls flyWeb17 apr. 2024 · oligonucleotide drug, known as ION-682884, that has been specifically designed to reduce production of the protein transthyretin by the liver, can slow or stop the progression of TTR amyloid cardiomyopathy as compared to historical controls, using advanced echocardiography highdown inn freshwaterWebThe benefits of ION-6582884 in hATTR-PN patients are yet unknown. Inotersen has been used in hATTR-PN patients and has shown to improve brain function and patient quality … highdown inn totland bayWebRx (ION-682884) is a ligand-conjugated antisense drug designed for receptor-mediated uptake by hepatocytes, the primary source of circulating transthyretin (TTR). Enhanced … highdown house yeoman way worthingWebION-682884 reduces the level of TTR in the blood of animals and healthy volunteers tested to date. Reducing the amount of TTR in participants blood may reduce the amount of … highdown hotel worthing menuWebEplontersen, formerly known as AKCEA-TTR-LRx and ION-682884, is an RNA-targeted therapy being co-developed by Ionis Pharmaceuticals and AstraZeneca for all forms of … how fast do ornamental pear trees grow